<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359228</url>
  </required_header>
  <id_info>
    <org_study_id>Salix Rifaximin Study</org_study_id>
    <nct_id>NCT01359228</nct_id>
  </id_info>
  <brief_title>Rifaximin Treatment of Papulopustular Rosacea</brief_title>
  <official_title>Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of rifaximin on skin symptoms in
      patients with rosacea by double-blinded, placebo-controlled, crossover study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 patients will be randomized into two groups.

      Group A will receive one rifaximin 550 mg tablet three times a day (1650 mg/day) for 14 days,
      and after a 4-week washout period, receive one placebo tablet three times a day for 14 days.

      Group B will receive placebo first, and then rifaximin with the same dosage schedule to Group
      A.

      Assessments will be performed before application and 4 weeks after the last dosage, for both
      of rifaximin and placebo.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA) Score of Rosacea Symptoms</measure>
    <time_frame>14 days</time_frame>
    <description>A response to treatment is defined as the achievement of an IGA score of '0 or 1' at endpoint for moderate to severe patients and achievement of an IGA score of '0' at endpoint for mild patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Achieving an IGA score of 0.</measure>
    <time_frame>14 days</time_frame>
    <description>Percentage of patients achieving an IGA score of '0' (cleared).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Rosacea</condition>
  <arm_group>
    <arm_group_label>Rifaximin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet three times a day for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin (XIFAXAN)</intervention_name>
    <description>Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days</description>
    <arm_group_label>Rifaximin</arm_group_label>
    <other_name>XIFAXAN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1 tablet three times a day for 14 days.</description>
    <arm_group_label>sugar pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  &gt; 18 years of age with rosacea defined as:

          -  3-40 papules/pustules and &lt; 2 nodules,

          -  A score of 2-4 on the Investigator Global Assessment

        Exclusion Criteria:

          -  Untreated pancreatic insufficiency

          -  Crohn's disease

          -  Ulcerative colitis

          -  Active celiac disease by clinical history

          -  End stage renal failure

          -  Less than 18 years old

          -  Pregnancy or positive pregnancy test

          -  Rosacea subtype 1 (no papules )

          -  Topical or oral antibiotics within 4 weeks

          -  Acne treatments within 4 weeks prior to randomization

          -  Systemic retinoids within 90 days

          -  Topical or systemic corticosteroids 4 weeks prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Steinhoff, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF, Dept. of Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF, CTSI, 12-Moffitt/Long Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <last_update_submitted>April 25, 2014</last_update_submitted>
  <last_update_submitted_qc>April 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rosacea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

